Systemic treatment for metastatic colorectal cancer
Issued Date
2023-03-14
Resource Type
ISSN
10079327
eISSN
22192840
Scopus ID
2-s2.0-85151043917
Pubmed ID
36970592
Journal Title
World Journal of Gastroenterology
Volume
29
Issue
10
Start Page
1569
End Page
1588
Rights Holder(s)
SCOPUS
Bibliographic Citation
World Journal of Gastroenterology Vol.29 No.10 (2023) , 1569-1588
Suggested Citation
Leowattana W., Leowattana P., Leowattana T. Systemic treatment for metastatic colorectal cancer. World Journal of Gastroenterology Vol.29 No.10 (2023) , 1569-1588. 1588. doi:10.3748/wjg.v29.i10.1569 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/82359
Title
Systemic treatment for metastatic colorectal cancer
Author(s)
Other Contributor(s)
Abstract
Significant progress has been achieved in the treatment of metastatic colorectal cancer (mCRC) patients during the last 20 years. There are currently numerous treatments available for the first-line treatment of mCRC. Sophisticated molecular technologies have been developed to reveal novel prognostic and predictive biomarkers for CRC. The development of next-generation sequencing and whole-exome sequencing, which are strong new tools for the discovery of predictive molecular biomarkers to facilitate the delivery of customized treatment, has resulted in tremendous breakthroughs in DNA sequencing technology in recent years. The appropriate adjuvant treatments for mCRC patients are determined by the tumor stage, presence of high-risk pathologic characteristics, microsatellite instability status, patient age, and performance status. Chemotherapy, targeted therapy, and immunotherapy are the main systemic treatments for patients with mCRC. Despite the fact that these novel treatment choices have increased overall survival for mCRC, survival remains optimal for individuals with non-metastatic disease. The molecular technologies currently being used to support our ability to practice personalized medicine; the practical aspects of applying molecular biomarkers to regular clinical practice; and the evolution of chemotherapy, targeted therapy, and immunotherapy strategies for the treatment of mCRC in the front-line setting are all reviewed here.